We are building a spare change investment platform to help you invest in companies working on a cure for Alzheimer’s.
Yet, most major pharmaceuticals have cut back on Alzheimer’s R&D as unprofitable, while smaller scientist led companies are left struggling for investment to develop promising scientific discoveries into a cure.
Alzheimer’s can be reversed in mice and many pathways to a cure have been discovered
Investment in companies working on a cure is scarce, stifling progress
A spare change investment platform to help millions invest in companies working on a cure for Alzheimer’s
InvestAcure has developed a formidable plan to end the roadblock imposed by insufficient capital to fund clinical trials necessary to discover effective cures for Alzheimer Disease. With so many major pharmaceutical companies leaving the space, it is even more imperative that we activate this approach immediately if we are to bring cures to families.
Many advances in research are not pursued by larger drug companies whose economic models favor palliative care (long-term repeat drug sales) over cures and drugs over diagnostics while smaller companies struggle to attract investment. InvestAcure's Common Need Investment model has the potential to alleviate some of this investment bottleneck. 70 million US adults have a relative with Alzheimer's. If a small percentage of this affinity group invest their spare-change, billions of dollars will be freed to fund approaches that might otherwise be neglected.
We can cure Alzheimer’s in our mice every week, but when it comes to clinical research where real progress needs to be made to cure people, there is simply no funding available.
We can't afford to sit idly by as research is stalled by a profit-driven agenda. With InvestAcure, we have a real solution to speed the path to a cure, by transitioning ownership of drug companies to millions of spare change investors committed to curing Alzheimer's.
The idea of having millions of people impacted by Alzheimer's join together as spare change investors, who own stock in drug companies, represents an innovative and potentially game-changing solution to the "valley of death" problem in the pharmaceutical industry. If scaled to full potential, it can help ensure that smaller scientist led drug companies to have the investment and support of their shareholders needed to pursue the development of cutting edge scientific breakthroughs into lifesaving drugs. I’m excited to join the team and do my part in realizing this world-changing vision.
When Harvey Pitt, former chairman of the SEC, visited MIT and mentioned InvestAcure as an example of a company using Finance for good, I was intrigued by the idea as it both spoke to my core values and was inspired by the research of my colleague, MIT Professor Andrew Lo, on the growing investment bottleneck stifling the development of lifesaving cures. I believe that Common Need Investment of spare change by millions committed to curing Alzheimer's is a potentially game-changing solution to that bottleneck. If successfully implemented, it can speed the development of lifesaving drugs and save countless lives. I'm excited to be an advisor to the InvestAcure team and do my part to help make this a reality.
Automatically round up transactions and invest just spare change in a portfolio of companies chosen by leading scientists
Set up your InvestAcure investment account online and connect your credit cards
Spend like normal. Your day-to-day transactions are rounded up to the nearest dollar and set aside for investment
With the guidance of leading scientists, your spare change is invested in companies working on a cure for Alzheimer's
When drug companies are owned by millions of spare change investors committed to curing Alzheimer's....
Seventy million Americans have a relative with Alzheimer's - every million spare change investors can mean $3 billion in investment over 5 years!
That would have 30X the impact of Bill Gates' recently publicized $100 million commitment to Alzheimer's research.
Your spare change will be invested in a portfolio of companies, chosen with the guidance of leading Alzheimer's researchers, based on their potential contribution to advancing the development of a cure.